Granisetron Articles
EUROPEAN STOCK COMMENT
22 November 1993
BRIBERY AND RIVALRY IN PHARMA SECTOR
22 November 1993
US ZOFRAN APPROVAL LIFTS GLAXO SHARES
23 August 1993
SCHERER AND GLAXO PACT ON ZOFRAN
5 July 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
GLAXO COMPROMISES OVER ONDANSETRON PATENT
26 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
EUROPE STOCK COMMENT
29 March 1993
SETBACKS COULD HIT GROWTH AT SK BEECHAM?
22 March 1993
EUROPE STOCK COMMENT
22 March 1993
DOUBLE TROUBLE FOR SMITHKLINE BEECHAM
22 March 1993
SB BEECHAM RESULTS; EXPLOITS STRENGTHS
1 March 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
SMITHKLINE BEECHAM ON TRACK
21 December 1992
SCHERING-PLOUGH IN UK CANCER DRUG DEAL
6 July 1992
Anti-emetics in chemotherapy
15 June 1992
COMPARATIVE STUDY CALL WITH ZOFRAN
23 March 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
JAPANESE YEAR-END APPROVALS
27 January 1992
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
